The stock of Cellectar Biosciences Inc (NASDAQ:CLRB) is a huge mover today! About 732,366 shares traded hands or 680.35% up from the average. Cellectar Biosciences Inc (NASDAQ:CLRB) has declined 49.73% since April 13, 2016 and is downtrending. It has underperformed by 53.66% the S&P500.
The move comes after 8 months positive chart setup for the $12.47M company. It was reported on Nov, 15 by Barchart.com. We have $5.00 PT which if reached, will make NASDAQ:CLRB worth $13.84M more.
According to Zacks Investment Research, “Cellectar Biosciences, Inc. is developing agents to detect, treat and monitor a broad spectrum of cancers. It uses a novel phospholipid ether platform technology as a targeted delivery and retention vehicle. Cellectar Biosciences Inc., formerly known as Novelos Therapeutics, Inc., is headquartered in Madison, Wisconsin.”
More notable recent Cellectar Biosciences Inc (NASDAQ:CLRB) news were published by: Reuters.com which released: “BRIEF-Cellectar Biosciences Inc Q3 loss from operations was $2.5 million” on November 11, 2016, also Seekingalpha.com with their article: “Cellectar Biosciences Readies New Offering As Trials Advance” published on November 10, 2016, Streetinsider.com published: “Cellectar Biosciences (CLRB) Taps INC Research (INCR) to Oversee CLR Phase 2 …” on November 15, 2016. More interesting news about Cellectar Biosciences Inc (NASDAQ:CLRB) were released by: Marketwatch.com and their article: “Plus the latest data from Realtor.com on 21 home markets across the US” published on February 24, 2014 as well as Finance.Yahoo.com‘s news article titled: “Cellectar Biosciences to Present at the LD Micro Invitational” with publication date: June 02, 2016.
CLRB Company Profile
Cellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., incorporated on June 24, 1996, is a clinical stage biopharmaceutical company. The Firm is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. The Company’s research and development program is based on its PDC cancer targeting delivery platform. The Company’s platform helps in discovery and development of a range of cancer targeting agents. The Company’s pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC’s. The Company’s PDC product portfolio includes CLR 131, CLR 125, CLR 124, CLR 1502 and CTX Product Portfolio.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.